tiprankstipranks
Trending News
More News >
Kintor Pharmaceutical Ltd (HK:9939)
:9939
Hong Kong Market
Advertisement

Kintor Pharmaceutical Ltd (9939) Financial Statements

Compare
3 Followers

Kintor Pharmaceutical Ltd Financial Overview

Kintor Pharmaceutical Ltd's market cap is currently HK$1.06B. The company's EPS TTM is HK$-0.209; its P/E ratio is ―; Kintor Pharmaceutical Ltd is scheduled to report earnings on March 26, 2025, and the estimated EPS forecast is HK$―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue¥ 5.00M¥ 0.00¥ 0.00¥ 34.23K¥ 0.00
Gross Profit¥ -4.73M¥ -42.23M¥ 0.00¥ 34.23K¥ 0.00
Operating Income¥ -144.57M¥ -1.06B¥ -969.12M¥ -839.60M¥ -399.74M
EBITDA¥ -128.37M¥ -1.06B¥ -956.45M¥ -829.09M¥ -396.33M
Net Income¥ -155.29M¥ -1.06B¥ -954.37M¥ -842.10K¥ -508.30M
Balance Sheet
Cash & Short-Term Investments¥ 147.42M¥ 455.50M¥ 875.08M¥ 1.06B¥ 1.39B
Total Assets¥ 515.13M¥ 869.23M¥ 2.06B¥ 2.07B¥ 1.85B
Total Debt¥ 133.01M¥ 253.92M¥ 286.39M¥ 159.73M¥ 221.70M
Net Debt¥ -14.41M¥ -191.58M¥ 285.52M¥ 158.80M¥ 220.64M
Total Liabilities¥ 221.05M¥ 411.12M¥ 559.95M¥ 412.83M¥ 343.54M
Stockholders' Equity¥ 294.08M¥ 458.11M¥ 149.52M¥ 165.52M¥ 150.79M
Cash Flow
Free Cash Flow¥ -199.08M¥ -390.30M¥ -988.73K¥ -1.13M¥ -449.92K
Operating Cash Flow¥ -199.08M¥ -387.58M¥ -961.26K¥ -1.05M¥ -380.88K
Investing Cash Flow¥ 20.03M¥ 3.27M¥ 67.19K¥ 92.00K¥ -439.73K
Financing Cash Flow¥ -119.67M¥ -33.46M¥ 815.75K¥ 857.42K¥ 1.78M
Currency in CNY

Kintor Pharmaceutical Ltd Earnings and Revenue History

Kintor Pharmaceutical Ltd Debt to Assets

Kintor Pharmaceutical Ltd Cash Flow

Kintor Pharmaceutical Ltd Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis